Business
Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada
-- FemCath® is the first intrauterine catheter that allows for selective evaluation of a fallopian tube with natural saline and air contrast -- -- FemCath is
About this update from Femasys Inc.
[{"type":"text","content":"-- FemCath® is the first intrauterine catheter that allows for selective evaluation of a fallopian tube with natural saline and air contrast -- -- FemCath is used in conjunction with Femasys’ FemVue® product as a baseline diagnostic test for infertility prior to therapeutic options like FemaSeed®, our insemination product recently approved in Canada -- ATLANTA, June 08, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Health Canada, the Public Health Agency of Canada, has granted product approval of FemCath®, the first intrauterine catheter that allows for selective evaluation of a fallopian tube with contrast. FemCath is used in conjunction with Femasys’ FemVue® device for an ultrasound-based diagnostic test as part of an infertility evaluation. Femasys’ diagnostic products are to be used prior to performing any infertility treatment, such as artificial insemination with Femasys’ FemaSeed® product, which was approved by Health Canada in April of this year. “Our momentum in the North American market continues with approval of another Femasys product in Canada, allowing for expanded commercial opportunities,” stated Kathy Lee-Sepsick, Femasys’ founder, president and, chief executive officer. “Given blocked fallopian tubes are a silent infertility factor affecting one out of three infertile women, it is critical to assess the viability of each fallopian tube, which can be achieved utilizing FemCath with our FemVue product. This essential diagnostic evaluation is required prior to performing the FemaSeed procedure, where sperm is delivered directly to one or both of the viable fallopian tubes where conception occurs. With our additional programs advancing this year, Femasys will continue its mission to bring much-needed technologies to women’s healthcare and build out our novel commercial suite of products.” FemCath utilizes Femasys’ proprietary delivery platform, which involves placement of balloon technology close to the opening of a selected fallopian tube for directed delivery of contrast. Femasys’ other biomedical solutions in development, FemaSeed and FemBloc®, utilize the same delivery platform for directed deliver...